STOCK TITAN

Acro Biomedical delays September 2026 quarterly report

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

ACRO BIOMEDICAL CO., LTD. notified that its Form 10-Q for the quarter ended September 30, 2026, will be delayed. The company expects to file it within five calendar days of the prescribed due date, citing a delay in assembling the required information.

Expected filing window Five calendar days Expected filing of the Form 10-Q for the quarter ended September 30, 2026, measured from the prescribed due date

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does ACBM expect to file its delayed Form 10-Q for the quarter ended September 30, 2026?

ACRO BIOMEDICAL CO., LTD. expects to file the report within five calendar days of the prescribed due date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

(Check One):

☐

Form 10-K

☐

Form 20-F

☐

Form 11-K

☒

Form 10-Q

☐

Form 10-D

☐

Form N-SAR

☐

Form N-CSR

 

For Period Ended: September 30, 2026

 

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-K

☐ Transition Report on Form N-SAR

 

For the Transition Period Ended: _____________________________________

 

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I - REGISTRANT INFORMATION

 

ACRO BIOMEDICAL CO., LTD.

Full Name of Registrant:

 

12175 Visionary Way, Suite 1160;

Address of Principal Executive Office (Street and number):

 

Fishers, Indiana 46038

City, State and Zip Code

 

 

 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

 

 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

☒

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

(c)

The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail the reason why Forms 10-K, 20-F, 11-K, 10-Q, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. 

  

The Company has encountered a delay in assembling the information required to be included in its quarterly report on the Form 10-Q for the period ending September 30, 2026. The Company expects to file its September 30, 2026, Form 10-Q quarter report with the U.S. Securities and Exchange Commission within five calendar days of the prescribed due date.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

Shao-Hsiang Shih

 

(317)

 

286-6788

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

☒ Yes ☐ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

   

 

2

 

 

 

ACRO BIOMEDICAL CO., LTD.

 

 

(Name of Registrant as Specified in Charter)

 

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026

By:

/s/ Shao-Hsiang Shih

 

 

 

Name: Shao-Hsiang Shih

 

 

 

Title: Chief Executive Officer and Chief Financial Officer

 

 

ATTENTION

 

Intentional misstatements or omissions of fact constitute Federal criminal violations. (See 18 U.S.C. 1001).

 

 

3

 

 

Keep reading